Browsing by Author "Haiman, C.A."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item A genome-wide association study of prostate cancer in West African men(Human Genetics, 2014-05) Cook, M.B.; Wang, Z.; Yeboah, E.D.; Tettey, Y.; Biritwum, R.B.; Adjei, A.A.; Tay, E.; Truelove, A.; Niwa, S.; Chung, C.C.; Chokkalingam, A.P.; Chu, L.W.; Yeager, M.; Hutchinson, A.; Yu, K.; Rand, K.A.; Haiman, C.A.; Hoover, R.N.; Hsing, A.W.; Chanock, S.J.Age-adjusted mortality rates for prostate cancer are higher for African-American men compared with those of European ancestry. Recent data suggest that West African men also have elevated risk for prostate cancer relative to European men. Genetic susceptibility to prostate cancer could account for part of this difference. We conducted a genome-wide association study (GWAS) of prostate cancer in West African men in the Ghana Prostate Study. Association testing was performed using multivariable logistic regression adjusted for age and genetic ancestry for 474 prostate cancer cases and 458 population-based controls on the Illumina HumanOmni-5 Quad BeadChip. The most promising association was at 10p14 within an intron of a long non-coding RNA (lncRNA RP11-543F8.2) 360 kb centromeric of GATA3 (p = 1.29E-7). In sub-analyses, SNPs at 5q31.3 were associated with high Gleason score (≥7) cancers, the strongest of which was a missense SNP in PCDHA1 (rs34575154, p = 3.66E-8), and SNPs at Xq28 (rs985081, p = 8.66E-9) and 6q21 (rs2185710, p = 5.95E-8) were associated with low Gleason score (<7) cancers. We sought to validate our findings in silico in the African Ancestry Prostate Cancer GWAS Consortium, but only one SNP, at 10p14, replicated at p < 0.05. Of the 90 prostate cancer loci reported from studies of men of European, Asian or African-American ancestry, we were able to test 81 in the Ghana Prostate Study, and 10 of these replicated at p < 0.05. Further genetic studies of prostate cancer in West African men are needed to confirm our promising susceptibility loci. © 2013 Springer-Verlag Berlin Heidelberg (outside the USA).Item Two susceptibility loci identified for prostate cancer aggressiveness.(Nature Communications, 2015-05) Berndt, S.I.; Wang, Z.; Yeager, M.; Alavanja, M.C.; Albanes, D.; Amundadottir, L.; Andriole, G.; Beane Freeman, L.; Campa, D.; Cancel-Tassin, G.; Canzian, F.; Cornu, J.-N.; Cussenot, O.; Diver, W.R.; Gapstur, S.M.; Grönberg, H.; Haiman, C.A.; Henderson, B.; Hutchinson, A.; Hunter, D.J.; Key, T.J.; Kolb, S.; Koutros, S.; Kraft, P.; Le Marchand, L.; Lindström, S.; Machiela, M.J.; Ostrander, E.A.; Riboli, E.; Schumacher, F.; Siddiq, A.; Stanford, J.L.; Stevens, V.L.; Travis, R.C.; Tsilidis, K.K.; Virtamo, J.; Weinstein, S.; Wilkund, F.; Xu, J.; Lilly Zheng, S.; Yu, K.; Wheeler, W.; Zhang, H.; Sampson, J.; Black, A.; Jacobs, K.; Hoover, R.N.; Tucker, M.; Chanock, S.J.Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10(-9)) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10(-8)). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10(-5)) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.